Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 19/20 | 0.57 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.57 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.57 |
| ▸ | MTOR | P42345 | 1/20 | 0.57 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2738335 | 0.90 | PIK3CA (0.60) | PIK3CAPIK3CDPIK3CBMTORPIK3CG | |
| SCHEMBL1899640 | 0.88 | PIK3CA (0.62) | PIK3CAPIK3CDPIK3CBMTORPIK3CG | |
| SCHEMBL1896729 | 0.85 | PIK3CA (0.74) | PIK3CAPIK3CDPIK3CBMTORPIK3CG | |
| SCHEMBL1899468 | 0.85 | PIK3CA (0.59) | PIK3CAPIK3CDPIK3CBMTORPIK3CG | |
| SCHEMBL189809 | 0.85 | ALDH1A1 (0.57) | PIK3CAPIK3CDPIK3CBMTORPIK3CG | |
| SCHEMBL1896972 | 0.83 | PIK3CA (0.59) | PIK3CAPIK3CDPIK3CBMTORPIK3CG | |
| SCHEMBL1898695 | 0.81 | PIK3CA (0.60) | PIK3CAPIK3CDPIK3CBMTORPIK3CG | |
| SCHEMBL12676338 | 0.81 | PIK3CA (0.62) | PIK3CAPIK3CDPIK3CBMTORPIK3CG | |
| SCHEMBL1898472 | 0.81 | PIK3CA (0.65) | PIK3CAPIK3CDPIK3CBMTORPIK3CG | |
| SCHEMBL1899525 | 0.80 | PIK3CA (0.61) | PIK3CAPIK3CDPIK3CBMTORPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940839-B1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kalpha | EXELIXIS INC (US) | 2013-07-31 | — | — | EP | disclosed |
| EP-2139484-B1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K ALPHA | EXELIXIS INC (US) | 2013-07-17 | — | — | EP | disclosed |
| WO-2012149308-A1 | METHOD OF TREATING LYMPHOMA USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K/MTOR | EXELIXIS, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012065019-A2 | PYRIDOPYRIMIDINONE INHIBITORS OF P13K ALPHA | EXELIXIS, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
| WO-2011100319-A1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K AND MTOR IN COMBINATION WITH AUTOPHAGY INHIBITORS | EXELIXIS, INC. (US) | 2011-08-18 | — | — | WO | disclosed |
| WO-2008124161-A1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K ALPHA | EXELIXIS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008021389-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |